J. Goldman & Co’s Merck MRK Stock Holding History

J. Goldman & Co’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-180,000	Closed	-$18.9M	–	801
2025 Q4	$18.9M	Buy	180,000 +100,000	+125%	+$9.39M	0.5%	55
2025 Q3	$6.71M	Buy	+80,000	New	+$6.59M	0.17%	164
2025 Q2	–	Sell	-60,000	Closed	-$5.39M	–	574
2025 Q1	$5.39M	Buy	+60,000	New	+$5.6M	0.13%	198
2024 Q3	–	Sell	-160,000	Closed	-$19.8M	–	560
2024 Q2	$19.8M	Buy	160,000 +100,000	+167%	+$12.9M	0.56%	53
2024 Q1	$7.92M	Buy	60,000 +45,000	+300%	+$5.55M	0.26%	117
2023 Q4	$1.64M	Sell	15,000 -86,300	-85%	-$8.96M	0.07%	203
2023 Q3	$10.4M	Buy	101,300 +13,800	+16%	+$1.49M	0.37%	87
2023 Q2	$10.1M	Buy	87,500 +12,500	+17%	+$1.42M	0.37%	84
2023 Q1	$7.98M	Buy	+75,000	New	+$8.1M	0.32%	98
2022 Q3	–	Sell	-125,100	Closed	-$11.4M	–	444
2022 Q2	$11.4M	Buy	+125,100	New	+$11.1M	0.56%	49
2013 Q3	–	Sell	-83,840	Closed	-$3.72M	–	297
2013 Q2	$3.72M	Buy	+83,840	New	+$3.74M	0.38%	84

Other funds holding MRK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

J. Goldman & Co's MRK Position: Q2 2025 in Review

J. Goldman & Co sold out of Merck (MRK) in Q2 2025, closing a stake of 17,518 shares — an estimated $1.57M sold.

J. Goldman & Co first reported a position in MRK in Q2 2013 and held it in 14 quarters. The position peaked at $79.9M in Q2 2024. 3,327 funds tracked by Wall St. Rank hold MRK as of Q2 2025.

J. Goldman & Co reported no remaining Merck position as of Q2 2025 after selling out during the quarter.
J. Goldman & Co sold 17,518 Merck shares in Q2 2025, an estimated $1.57M.
J. Goldman & Co first reported a position in Merck in Q2 2013 and held it in 14 quarters.
J. Goldman & Co's Merck position peaked at $79.9M in Q2 2024.
3,327 funds tracked by Wall St. Rank held Merck as of Q2 2025.

Based on J. Goldman & Co's 13F filing for Q2 2025, filed 14 Aug 2025.